CALGARY, Alberta--(BUSINESS WIRE)--July 11, 2005--Resverlogix Corp. (TSX:RVX) ("Resverlogix"), is pleased to announce that exciting new research has been validated in its lead cardiovascular technology program NEXVAS(TM). In pre-clinical trials the company has now validated in an animal model a rapid onset of Apo AI enhancement. These findings are novel and will build upon the commercial opportunity of the NEXVAS(TM) chronic (long term) program and expand the company's presence in the important acute (short term) Cardiovascular Market Segment.
